Galux
AI-driven de novo protein design for drug discovery
Galux uses deep learning models and lab validation to create new therapeutic proteins from scratch. The Seoul-based company's GaluxDesign platform has attracted partnerships with major pharma including Celltrion, LG Chem, and Boehringer Ingelheim, positioning it as a leader in Korea's AI drug discovery ecosystem.
Antibody Design, Generative Chemistry
Funding
$47M
Total raised
$29M
Led by InterVest
InterVest · DAYLI Partners · Korea Development Bank
Technology
GaluxDesign platform using deep learning for de novo therapeutic protein design. Integrates computational protein generation with experimental validation to create novel antibodies and protein therapeutics.
Partnerships
Similar companies
Absci Corporation
AI-powered de novo antibody design and creation
preclinical · 2011Antiverse
Generative AI for antibody CDR design
preclinical · 2018Generate:Biomedicines
Generative AI for de novo protein therapeutic design
preclinical · 2020Xaira Therapeutics
AI-native drug discovery with $1B+ launch — largest in biotech history
preclinical · 2024Get updates on Galux
We'll notify you when we publish updates about Galux.